RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: UCARsgen Biotech Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
A pre-treatment pill may supercharge cancer-fighting immune cells
Disease control Not yet recruitingThis early-phase trial tests whether giving the drug iberdomide before collecting a patient's T cells can improve the fitness of those cells for CAR-T therapy. The study enrolls adults with relapsed or refractory multiple myeloma who are already scheduled for standard CAR-T treat…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Shambavi Richard • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New dosing strategy aims to reduce eye side effects in myeloma treatment
Disease control Not yet recruitingThis phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR-T therapy RN9101 targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial
Disease control Not yet recruitingThis early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a withdrawn myeloma drug make a comeback with a gentler schedule?
Disease control Not yet recruitingThis study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug elranatamab tested in Real-World chinese myeloma patients
Disease control Not yet recruitingThis study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New study monitors infection risks in advanced myeloma drug
Knowledge-focused Not yet recruitingThis Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC